Abstract
BackgroundThe exact association between clinical and biochemical hyperandrogenism (HA) is heterogeneous and cannot be ascertained, especially in normoandrogenic women.ObjectivesEvaluate any association between clinical phenotypes and biochemical parameters of HA in premenopausal women with female pattern hair loss (FPHL).Materials and methodsA cross-sectional observational study on 362 women, who were assessed for general characteristics, the different FPHL severities by Sinclair's score, hirsutism by modified Ferriman-Gallwey (mFG) score. Evaluation for biochemical HA included total, calculated free and bioavailable testosterone (TT), free testosterone (FT), and bioavailable testosterone (BT), respectively, and dehydroepiandrosterone sulfate. The variables of clinical HA were FPHL, hirsutism, and acne.ResultsThe enrolled young premenopausal women's age range was (14-47 years). Around 78% were overweight or obese women. Eighty-percent of women had a mild FPHL, with a median of three years, where 2/3 of women had a duration <3 years with no significant relationship to FPHL severity. About 73% of women had either a mild to moderate hirsutism, and around 16% had acne. The biochemical HA was confirmed in around 52% of women (n=188), who show high levels of calculated FT. The calculated BT is high in 78.5% of women (n=284). The means of HA's biochemical indicators were in their reference ranges or slightly above, with no specific change pattern with the corresponding FPHL severity. None of these parameters had a significant relationship with the severity of FPHL. The FPHL duration was not affected by any presumed variable of clinical or biochemical HA.ConclusionsFPHL severity was associated with other clinical HA signs like hirsutism and acne, but not to HA's biochemical parameter. Other parameters, like sex hormone-binding globulin (SHBG), and BMI, had no significant relation to the FPHL severity.
Highlights
Female pattern hair loss (FPHL) is the most common nonscarring diffuse hair loss disorder of a characteristic pattern in reproductive age women, with an uncertain relationship with androgens [1,2,3]
A cross-sectional observational study on 362 women, who were assessed for general characteristics, the different female pattern hair loss (FPHL) severities by Sinclair's score, hirsutism by modified Ferriman-Gallwey score
The calculated bioavailable testosterone (BT) is high in 78.5% of women (n=284)
Summary
Female pattern hair loss (FPHL) is the most common nonscarring diffuse hair loss disorder of a characteristic pattern in reproductive age women, with an uncertain relationship with androgens [1,2,3]. The main histopathological changes involve the hair follicles' miniaturization, with a consequent decline in hair density at different scalp regions, especially the scalp [1]. All phenotypic presentations of FPHL involve the bitemporal and vertex region in different severities. The study's objective was to evaluate any possible association between hyperandrogenism's clinical phenotype and biochemical parameters in premenopausal women with FPHL. How to cite this article Odhaib S A, Al Hamdi K, Mansour A A (November 27, 2020) Is There Any Association Between Clinical and Biochemical Hyperandrogenism in Women With Female Pattern Hair Loss?. The exact association between clinical and biochemical hyperandrogenism (HA) is heterogeneous and cannot be ascertained, especially in normoandrogenic women
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
